♥ HF Guideline NavigatorESC 2026

Quick reference

Frequently needed definitions and tables, transcribed from the guideline (pp. 8–9, 15–17, 22).

Definition of heart failure (§3.1)

A clinical syndrome comprising signs and/or symptoms caused by structural and/or functional abnormalities of the heart that result in elevated intracardiac pressures and/or inadequate cardiac output at rest and/or during exercise. Objective evidence of cardiogenic congestion and supportive diagnostic tests are needed. Asymptomatic people are classified as at risk (stage A) or pre-HF (stage B).

Phenotypes by LVEF (§3.3.1)

The 2026 guideline eliminates HFmrEF and uses two phenotypes.

HFrEF

LVEF <50% and symptoms and/or signs of HF.

HFpEF

LVEF ≥50%, symptoms and/or signs of HF, and objective evidence of structural and/or functional abnormalities consistent with LV diastolic dysfunction/raised filling pressures, supported by raised natriuretic peptides.

Other classifications: de novo vs pre-existing; chronic vs decompensated; isolated left-sided vs right-sided vs combined (§3.3.3).

NYHA functional class (Table 8)

Class I
No limitation of physical activity. Ordinary activity does not cause undue breathlessness, fatigue or palpitations.
Class II
Slight limitation. Comfortable at rest, but ordinary activity causes undue breathlessness, fatigue or palpitations.
Class III
Marked limitation. Comfortable at rest, but less than ordinary activity causes undue breathlessness, fatigue or palpitations.
Class IV
Unable to carry on any physical activity without discomfort; symptoms may be present at rest.

NT-proBNP age-adjusted thresholds (§5.1.1)

Outpatient levels above which HF is “likely”: ≥125 pg/mL for age <50 y, ≥250 pg/mL for 50–75 y, ≥500 pg/mL for >75 y (HFA-ESC consensus). The 2021 single rule-out value was <125 pg/mL NT-proBNP (<35 pg/mL BNP). Obesity lowers natriuretic peptide levels — interpret with caution. See Table 9 and Figure 4 on pp. 23–24.

Read §5.1.1 →

Classes of recommendation (Table 1)

  • Class I“is recommended / indicated”
  • Class IIa“should be considered”
  • Class IIb“may be considered”
  • Class III“is not recommended”

Levels of evidence — therapy (Table 2)

Level A
Conclusive evidence, usually from at least two adequately powered RCTs free of major bias (meta-analysis P <0.005).
Level B1
Suggestive evidence from at least one adequately powered RCT free of major bias, or a meta-analysis of such RCTs (P <0.05).
Level B2
Limited evidence from ≥2 adequately powered non-randomized studies with careful bias control, or a meta-analysis of small underpowered RCTs.
Level C
Preliminary evidence: non-randomized studies without careful bias control, a single small RCT, or expert consensus.

Treatment nomenclature (§3.3.4)

FMT foundational medical therapy · AMT additional medical therapy · GDIT guideline-directed interventional therapy. FMT for HFrEF: ACE-I/ARNI (or ARB), beta-blocker, MRA, SGLT2-I; SGLT2-I and MRA are recommended in all symptomatic HF regardless of LVEF. Doses are in the drug dose table.